IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-19408-2.html
   My bibliography  Save this article

Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer

Author

Listed:
  • Mélanie Desbois

    (Genentech, Inc.)

  • Akshata R. Udyavar

    (Genentech, Inc.)

  • Lisa Ryner

    (Genentech, Inc.)

  • Cleopatra Kozlowski

    (Genentech, Inc.)

  • Yinghui Guan

    (Genentech, Inc.)

  • Milena Dürrbaum

    (Genentech, Inc.)

  • Shan Lu

    (Genentech, Inc.)

  • Jean-Philippe Fortin

    (Genentech, Inc.)

  • Hartmut Koeppen

    (Genentech, Inc.)

  • James Ziai

    (Genentech, Inc.)

  • Ching-Wei Chang

    (Genentech, Inc.)

  • Shilpa Keerthivasan

    (Genentech, Inc.)

  • Marie Plante

    (Laval University Cancer Research Center, Hôtel-Dieu-de-Québec, Centre Hospitalier Universitaire (CHU) de Québec)

  • Richard Bourgon

    (Genentech, Inc.)

  • Carlos Bais

    (Genentech, Inc.)

  • Priti Hegde

    (Genentech, Inc.)

  • Anneleen Daemen

    (Genentech, Inc.)

  • Shannon Turley

    (Genentech, Inc.)

  • Yulei Wang

    (Genentech, Inc.)

Abstract

Close proximity between cytotoxic T lymphocytes and tumour cells is required for effective immunotherapy. However, what controls the spatial distribution of T cells in the tumour microenvironment is not well understood. Here we couple digital pathology and transcriptome analysis on a large ovarian tumour cohort and develop a machine learning approach to molecularly classify and characterize tumour-immune phenotypes. Our study identifies two important hallmarks characterizing T cell excluded tumours: 1) loss of antigen presentation on tumour cells and 2) upregulation of TGFβ and activated stroma. Furthermore, we identify TGFβ as an important mediator of T cell exclusion. TGFβ reduces MHC-I expression in ovarian cancer cells in vitro. TGFβ also activates fibroblasts and induces extracellular matrix production as a potential physical barrier to hinder T cell infiltration. Our findings indicate that targeting TGFβ might be a promising strategy to overcome T cell exclusion and improve clinical benefits of cancer immunotherapy.

Suggested Citation

  • Mélanie Desbois & Akshata R. Udyavar & Lisa Ryner & Cleopatra Kozlowski & Yinghui Guan & Milena Dürrbaum & Shan Lu & Jean-Philippe Fortin & Hartmut Koeppen & James Ziai & Ching-Wei Chang & Shilpa Keer, 2020. "Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer," Nature Communications, Nature, vol. 11(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19408-2
    DOI: 10.1038/s41467-020-19408-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-19408-2
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-020-19408-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. I.-M. Launonen & N. Lyytikäinen & J. Casado & E. A. Anttila & A. Szabó & U.-M. Haltia & C. A. Jacobson & J. R. Lin & Z. Maliga & B. E. Howitt & K. C. Strickland & S. Santagata & K. Elias & A. D. D’And, 2022. "Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    2. Monika Licaj & Rana Mhaidly & Yann Kieffer & Hugo Croizer & Claire Bonneau & Arnaud Meng & Lounes Djerroudi & Kevin Mujangi-Ebeka & Hocine R. Hocine & Brigitte Bourachot & Ilaria Magagna & Renaud Lecl, 2024. "Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway," Nature Communications, Nature, vol. 15(1), pages 1-27, December.
    3. Mengxue Zhou & Jiaxin Wang & Jiaxing Pan & Hui Wang & Lujia Huang & Bo Hou & Yi Lai & Fengyang Wang & Qingxiang Guan & Feng Wang & Zhiai Xu & Haijun Yu, 2023. "Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19408-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.